These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 28820433)

  • 21. Anti-human papillomavirus therapeutics: facts & future.
    Bharti AC; Shukla S; Mahata S; Hedau S; Das BC
    Indian J Med Res; 2009 Sep; 130(3):296-310. PubMed ID: 19901439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
    Tomson TT; Roden RB; Wu TC
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute exercise does not improve immune response to HPV vaccination series in adolescents.
    Bohn-Goldbaum E; Lee VY; Skinner SR; Frazer IH; Khan BA; Booy R; Edwards KM
    Papillomavirus Res; 2019 Dec; 8():100178. PubMed ID: 31319174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on human papillomavirus vaccines for cervical cancer.
    Steller MA
    Curr Opin Investig Drugs; 2002 Jan; 3(1):37-47. PubMed ID: 12054070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M; Gissmann L; Nardelli-Haefliger D
    Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of HPV infection and related cancer through vaccination.
    Tran NP; Hung CF; Roden R; Wu TC
    Recent Results Cancer Res; 2014; 193():149-71. PubMed ID: 24008298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immune response in cervical cancer. Strategies for the development of therapeutic vaccines].
    Mora-García ML; Monroy-García A
    Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S206-11. PubMed ID: 26462518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
    Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
    Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vaccination against human papillomavirus for the prevention of cervical cancer].
    Quint WG; ter Harmsel WA; van Doorn LJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1380-4. PubMed ID: 16841585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
    Lee SJ; Yang A; Wu TC; Hung CF
    J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
    Struyf F; Colau B; Wheeler CM; Naud P; Garland S; Quint W; Chow SN; Salmerón J; Lehtinen M; Del Rosario-Raymundo MR; Paavonen J; Teixeira JC; Germar MJ; Peters K; Skinner SR; Limson G; Castellsagué X; Poppe WA; Ramjattan B; Klein TD; Schwarz TF; Chatterjee A; Tjalma WA; Diaz-Mitoma F; Lewis DJ; Harper DM; Molijn A; van Doorn LJ; David MP; Dubin G;
    Clin Vaccine Immunol; 2015 Feb; 22(2):235-44. PubMed ID: 25540273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of human papillomavirus genotyping.
    Choi YJ; Park JS
    J Gynecol Oncol; 2016 Mar; 27(2):e21. PubMed ID: 26768784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPV proteins as targets for therapeutic intervention.
    Sterlinko Grm H; Banks L
    Antivir Ther; 2004 Oct; 9(5):665-78. PubMed ID: 15535404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
    Ault K; Reisinger K
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE; Vuocolo S
    Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
    Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
    Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
    Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
    Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [HPV immunization for the prevention of cervical cancer].
    Mougin C; Bourgault-Villada I; Coursaget P
    Presse Med; 2009 Dec; 38(12):1750-68. PubMed ID: 19765945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventive and therapeutic HPV vaccines.
    Monie A; Hung CF; Wu TC
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1038-50. PubMed ID: 18058574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.